When does rheumatoid arthritis begin and why do we need to know?

Arthritis and Rheumatism

Volumn 43, Issue 3, 2000, Pages 473-484

  Kim, Janet M ^a   Weisman, Michael H ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RHEUMATOID FACTOR;

CHRONIC DISEASE; DISABILITY; DISEASE MARKER; DISEASE PREDISPOSITION; DISEASE SEVERITY; IMMUNOGENETICS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

AGE OF ONSET; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MASSACHUSETTS; MICHIGAN;

EID: 0034041155     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200003)43:3<473::AID-ANR1>3.0.CO;2-A     Document Type: Review

References (83)

1. Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am 1993;19:123-51.
2. Brooks PM. The Heberden Oration 1997. Treatment of rheumatoid arthritis: from symptomatic relief to potential cure. Br J Rheumatol 1998;37:1265-71.
3. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995;54:944-7.
4. Mottonen T. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis 1988;47:648-53.
5. Van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995;34 Suppl 2:74-8.
6. Devlin J, Gough AK, Huissoon A, Perkins P, Holder R, Reece R, et al. The acute phase and function in early rheumatoid arthritis: CRP levels correlate with functional outcome. J Rheumatol 1997; 24:9-13.
7. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996;39:616-22.
8. Stenger AA, van Leeuwcn MA, Houtman PM, Bruyn GAW, Speerstra F, Barendsen BC, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998;37:1157-63.
9. Weinblatt ME. Rheumatoid arthritis: treat now, not later! Ann Intern Med 1996;124:773-4.
10. Epstein WV. Expectation bias in rheumatoid arthritis clinical trials: the anti-CD4 monoclonal antibody experience. Arthritis Rheum 1996;39:1773-80.
11. Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA. 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958;9:175-6.
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
13. Dugowson CE, Nelson JL, Koepsell TD. Evaluation of the 1987 revised criteria for rheumatoid arthritis in a cohort of newly diagnosed female patients. Arthritis Rheum 1990;33:1042-6.
14. Harrison BJ, Symmons DPM, Barrett EM, Silman AJ. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. J Rheumatol 1998;25:2324-30.
15. Chan K-WA, Felson DT, Yood RA, Walker AM. The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis Rheum 1994;37:814-20.
16. Van der Horst-Bruinsma IE, Speyer E, Visser H, Breedveld FC, Hazes JMW. Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care. Br J Rheumatol 1998;37:1084-8.
17. Tunn EJ, Bacon PA. Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. Br J Rheumatol 1993;32:97-103.
18. Harrison BJ, Symmons CPM, Brennan P, Barrett EM, Silman AJ. Natural remission in inflammatory polyarthritis: issues of definition and prediction. Br J Rheumatol 1996;35:1096-100.
19. Nissila M, Isomaki H, Kaarela K, Kiviniemi P, Martio J, Sarna S. Prognosis of inflammatory joint diseases - a 3 year follow-up study. Scand J Rheumatol 1983;12:33-8.
20. Speyer I, Hazes JM, Breedveld FC. Recruitment of patients with early rheumatoid arthritis - the Netherlands experience. J Rheumatol 1996;23 Suppl 44:84-5.
21. Hulsemann JL, Zeidler H. Undifferentiated arthritis in an early synovitis out-patient clinic. Clin Exp Rheumatol 1995;13:37-43.
22. Machold KP, Eberl G, Leeb BF, Nell V, Windisch B, Smolen JS. Early arthritis therapy: rationale and current approach. J Rheumatol 1998;25 Suppl 53:13-9.
23. Mikkelsen WM, Dodge H. A four year follow-up of suspected rheumatoid arthritis: the Tecumseh, Michigan, community health study. Arthritis Rheum 1969;12:87-91.
24. O'Sullivan JB, Cathcart ES. The prevalence of rheumatoid arthritis: follow-up evaluation of the effect of criteria on rates in Sudbury, Massachusetts. Ann Intern Med 1972;76:573-7.
25. Young A, Bielawska C, Corbett M, Roitt I. A prospective study of early onset rheumatoid arthritis over fifteen years: prognostic features and outcome. Clin Rheumatol 1987;6 Suppl 2:12-9.
26. Wolfe F, Ross K, Hawley DJ, Roberts FK, Cathey MA. The prognosis of rheumatoid arthritis and undifferentiated polyarthritis syndrome in the clinic: a study of 1141 patients. J Rheumatol 1993;20:2005-9.
27. Gough A, Faint J, Salmon M, Hassell A, Wordsworth P, Pilling D, et al. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum 1994;37:1166-70.
28. Prevoo ML, van Gestel AM, van't Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PLCM. Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996;35:1101-5.
29. Van der Heijde DMFM, van't Hof MA, van Riel PLCM, Theunissc LM, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
30. Masi AT, Feigenbaum SL, Kaplan SB. Articular patterns in the early course of rheumatoid arthritis. Am J Med 1983;75:16-26.
31. Mottonen T, Paimela L, Leirisalo-Repo M, Kautiainen H, Ilonen J, Hannonen P. Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy. Ann Rheum Dis 1998; 57:533-9.
32. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
33. Van der Heijde DM, van Riel PL, van Leeuwen MA, van't Hof MA, van Rijswijk MH, van de Putte LBA. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: a prospective follow-up study of 147 patients. Br J Rheumatol 1992;31:519-25.
34. Harrison BJ, Symmons DPM, Brennan P, Bankhead CR, Barrett EM, Scott DGI, et al. Inflammatory polyarthritis in the community is not a benign disease: predicting functional disability one year after presentation. J Rheumatol 1996;23:1326-31.
35. Brennan P, Harrison B, Barrett E, Chakravarty K, Scott D, Silman A, et al. A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study. BMJ 1996;313:471-6.
36. Feigenbaum SL, Masi AT, Kaplan SB. Prognosis in rheumatoid arthritis - a longitudinal study of newly diagnosed younger adult patients. Am J Med 1979;66:377-84.
37. Aho K, Heliovaara M, Maatela J, Tuomi T, Palosuo T. Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol 1991;18:1282-4.
38. Aho K, Palosuo T, Raunio V, Puska P, Aromaa A, Salonen JT. When does rheumatoid disease start? Arthritis Rheum 1985;28: 485-9.
39. Young B, Mallya R, Leslie R, Clark C, Hamhlin T. Antikeratin antibodies in rheumatoid arthritis. BMJ 1979;2:97-9.
40. Nienhuis R, Mandema E. A new serum factor in patients with rheumatoid arthritis: the perinuclear factor. Ann Rheum Dis 1964;23:302-5.
41. Hassfeld W, Steiner G, Hartmuth K, Kolarz G, Scherak O, Graninger W, et al. Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum 1989;32:1515-20.
42. Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girhal E, Durieux JJ, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific antibodies. J Clin Invest 1995;95:2672-9.
43. Schellekens GA, de Jong BAW, van den Hoogen FHJ, van de Putte LBA, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273-81.
44. Steiner G, Hartmuth K, Skriner K, Maurer-Fogy I, Sinski A, Thalmann E, et al. Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. J Clin Invest 1992;90:1061-6.
45. Hassfeld W, Steiner G, Graninger W, Witzmann G, Schweitzer H, Smolen JS. Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br J Rheumatol 1993;32:199-203.
46. Cordonnier C, Meyer O, Palazzo E, de Bandt M, Elias A, Nicaise P, et al. Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor. Br J Rheumatol 1996;35:620-4.
47. Depres N, Boire G, Lopez Longo FJ, Menard HA. The Sa system: a novel antigen antibody system specific for rheumatoid arthritis. J Rheumatol 1994;21:1027-33.
48. Hayem G, Chazerain P, Combe B, Elias A, Haim T, Nicaise P, et al. Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol 1999;26:7-13.
49. Hueber W, Hassfeld W, Smolen JS, Steiner G. Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis. Rheumatology 1999;38:155-9.
50. Cunnane G, Grehan S, Geoghan S, Whitehead AS, Bresnihan B, FitzGerald O. Measurement of serum amyloid A in the assessment of early inflammatory arthritis [abstract]. Arthritis Rheum 1998;41 Suppl 9:S237.
51. Zvaifler N, Boyle D, Firestein G. Early synovitis - synoviocytes and mononuclear cells. Semin Arthritis Rheum 1994;23 Suppl 2:11-6.
52. Kraan MC, Haringman JJ, Post WJ, Versendaal J, Breedveld FC, Tak PP. Immunohistology of synovial tissue for the differential diagnosis of early arthritis [abstract]. Arthritis Rheum 1998;41 Suppl 9:S23H.
53. Wollheim FA. Predictors of joint damage in rheumatoid arthritis. APMIS 1996;104:81-93.
54. Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978;298:869-71.
55. Jaraquemada D, Ollier W, Awad J, Young A, Silman A, Roitt IM, et al. HLA and rheumatoid arthritis: a combined analysis of 440 British patients. Ann Rheum Dis 1986;45:627-36.
56. Suarez-Almazor ME, Tao S, Moustarah F, Russell AS, Maksymowych W. HLA-DR1, DR4, and DRB1 disease related subtypes in rheumatoid arthritis: association with susceptibility but not severity in a city wide community based study. J Rheumatol 1995;22:2027-33.
57. Nelson JL, Dugowson CE, Koepsell TD, Voigt LF, Branchaud AM, Barrington RA, et al. Rheumatoid factor. HLA-DR4, and allelic variants of DRB1 in women with recent-onset rheumatoid arthritis. Arthritis Rheum 1994;37:673-80.
58. Ploski R, Mellbye OJ, Ronningen KS, Forre O, Thorsby E. Seronegative and weakly seropositive rheumatoid arthritis differ from clearly seropositive rheumatoid arthritis in HLA class II associations. J Rheumatol 1994;21:1397-402.
59. Salvarani C, Macchioni P, Mantovani W, Rossi F, Veneziani M, Boiardi L, et al. Extraarticular manifestations of rheumatoid arthritis and HLA antigens in northern Italy. J Rheumatol 1992; 19:242-6.
60. Olsen NJ, Callahan LF, Brooks RH, Nance EP, Kaye JJ, Stastny P, et al. Associations of HLA-DR4 with rheumatoid factor and radiographic severity in rheumatoid arthritis. Am J Med 1988;84: 257-64.
61. Walton K, Dyer PA, Grennan DM, Haeney M, Harris R. Clinical features of autoantibodies and HLA-DR antigens in rheumatoid arthritis. J Rheumatol 1985;12:223-6.
62. Dobloug JH, Førre Ø, Kåss E, Thorsby E. HLA antigens and rheumatoid arthritis: association between HLA-DRw4 positivity and IgM rheumatoid factor production. Arthritis Rheum 1980;23: 309-13.
63. Al-Jarallah KF, Buchanan WW, Sastry A, Singal DP. Seronegative rheumatoid arthritis and HLA-DR4. J Rheumatol 1994;21:190-3.
64. Boerbooms AMT, Westgeest AAA, Reckcrs P, van de Putte LBA. Immunogenetic heterogeneity of seronegative rheumatoid arthritis and the antiperinuclear factor. Ann Rheum Dis 1990;49:15-7.
65. Calin A, Elswood J, Klouda PT. Destructive arthritis, rheumatoid factor, and HLA-DR4: susceptibility versus severity, a case-control study. Arthritis Rheum 1989;32:1221-5.
66. Panayi GS, Celinska E, Emery P, Griffin J, Welsh KI, Grahamc R, et al. Seronegative and seropositive rheumatoid arthritis: similar diseases. Br J Rheumatol 1987;26:172-80.
67. De Jongh BM, van Romunde LK, Valkenburg HA, de Lange GG, van Rood JJ. Epidemiological study of HLA and GM in rheumatoid arthritis and related symptoms in an open Dutch population. Ann Rheum Dis 1984;43:613-9.
68. Gran JT, Husby G, Thorsby E. The association between rheumatoid arthritis and the HLA antigen DR4. Ann Rheum Dis 1983; 42:292-6.
69. Alarcón GS, Koopman WJ, Acton RT, Barger BO. Seronegative rheumatoid arthritis: a distinct immunogenetic disease? Arthritis Rheum 1982;25:502-7.
70. Thomson W, Harrison B, Ollier B, Wiles N, Payton T, Barrett J, et al. Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis. Arthritis Rheum 1999;42:757-62.
71. Weyand CM, McCarthy TG, Goronzy JJ. Correlation between disease phenotype and genetic heterogeneity in rheumatoid ar-thritis. J Clin Invest 1995:95:2120-6.
72. Thomson W, Pepper L, Payton A, Carthy D, Scott D, Oilier W, et al. Absence of an association between HLA-DRB1*04 and rheu-matoid arthritis in newly diagnosed cases from the community. Ann Rheum Dis 1993;52:539-41.
73. Eberhardt KB, Rydgren LC, Pettersson H, Wollheim FA. Early rheumatoid arthritis-onset, course, and outcome over 2 years. Rheumatol Int 1990;10:135-42.
74. Van Leeuwen MA, van der Heijde DM, van Rijswijk MH, Houtman PM, van Riel PLCM, van de Putte LBA, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis: a comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 1994;21:425-9.
75. Van der Heide A, Remme CA, Hofman DM, Jacobs JWG, Bijlsma JWJ. Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum 1995;38: 1466-74.
76. Corbett M, Dalton S, Silman A, Shipley M. Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. Br J Rheumatol 1993;32:717-23.
77. Eberhardt KB, Fex E. Functional impairment and disability in early rheumatoid arthritis - development over 5 years. J Rheumatol 1995;22:1037-42.
78. Van Zeben D, Hazes JMW, Zwinderman AH, Cats A, Schreuder GMT, D'Amaro J, et al. Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis: results of a followup study. Arthritis Rheum 1991;34:822-30.
79. Eberhardt KB, Grubb R, Johnson U, Pettersson H. HLA-DR antigens, Gm allotypes and antiallotypes in early rheumatoid arthritis - their relation to disease progression. J Rheumatol 1993; 20:1825-9.
80. Paimela L, Leirisalo-Repo M, Helve T, Koskimies S. The prognostic value of HLA DR4 and B27 antigens in early rheumatoid arthritis. Scand J Rheumatol 1993;22:220-4.
81. Higami K, Hakoda M, Matsuda Y, Ueda H, Kashiwazaki S. Lack of association of HLA-DRB1 genotype with radiologic progression in Japanese patients with early rheumatoid arthritis. Arthritis Rheum 1997;40:2241-7.
82. Wagner U, Kaltenhäuser S, Sauer H, Arnold S, Seidel W, Häntzschel H, et al. HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum 1997;40: 341-51.
83. Van Jaarsveld CHM, Otten HG, Jacobs JWG, Kruize AA, Brus HLM, Bijlsma JWJ. Association of HLA-DR with susceptibility to and clinical expression of rheumatoid arthritis: re-evaluation by means of genomic tissue typing. Br J Rheumatol 1998;37:411-6.